How ENBREL Works

Plaque psoriasis and psoriatic arthritis are diseases of the immune system. In patients with plaque psoriasis and psoriatic arthritis, certain immune cells are activated and play an important role. They overproduce inflammatory proteins such as tumor necrosis factor (TNF). These proteins can cause inflammation in the skin, which can cause skin cells to grow too quickly. The skin cells build up and form raised, red patches, often with silvery scales, known as psoriatic lesions. These plaques may itch, be painful, and can bleed. This protein also causes inflammation in the joints, which can create pain and progressive joint damage.

Working below the skin's surface

Biologic therapies like ENBREL don't just work on the surface of the skin. They work on the immune system to help lessen the joint pain and help stop joint damage associated with psoriatic arthritis. ENBREL blocks the activity of excess TNF to reduce the inflammation that causes psoriatic lesions and joint pain. Because ENBREL works on your immune system, it may lower the ability of your immune system to fight infections and may raise other safety concerns. If you have any sign of an infection including a fever, cough, flu-like symptoms, or have any open sores on your body, call your doctor. Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

ENBREL is indicated for adults with psoriatic arthritis and chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Get a closer look at how ENBREL works

Watch this short video to see how the immune system plays a role in plaque psoriasis. See how ENBREL targets the immune system to reduce the overproduction of skin cells to help you get clearer skin.

Prescription ENBREL is taken by injection.


Psoriatic Arthritis
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.

Moderate to Severe Plaque Psoriasis
ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data
Psoriatic Arthritis
  • ENBREL was shown to be effective in about 50% of patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
Moderate to Severe Plaque Psoriasis
  • In medical studies, nearly half of patients saw 75% skin clearance in 3 months. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months.
Want more information?

Sign up today to receive information about ENBREL.

Sign up to receive information about ENBREL